Cargando…
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
BACKGROUND: We previously showed that the bacterial lipopeptide Pam(3)Cys-Ser-Ser, meanwhile established as a toll-like receptor (TLR) 1/2 ligand, acts as a strong adjuvant for the induction of virus specific CD8(+) T cells in mice, when covalently coupled to a synthetic peptide. CASE PRESENTATION:...
Ejemplares similares
-
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018) -
A role for artificial intelligence in molecular imaging of infection and inflammation
por: Schwenck, Johannes, et al.
Publicado: (2022) -
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
por: Rammensee, Hans-Georg, et al.
Publicado: (2021) -
Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
por: Martens, Alexander, et al.
Publicado: (2014) -
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo
(18)F-FDG-PET
por: Schwenck, Johannes, et al.
Publicado: (2020)